TruScreen Market Access Developments - Indonesia and Kenya

NZX/ASX Announcement

8 March 2024

TruScreen Market Access Developments - Indonesia and Kenya

TruScreen Group Limited (NZX/ASX:TRU) is pleased to announce planning in progress for clinical evaluation trials in Indonesia and Kenya which are a prelude to wider market access in future years. Indonesia has an addressable screening market of 95 million while Kenya has an addressable screening market of 17 million.

These initiatives are being driven by Key Opinion Leaders (KOL’s) in these countries through private healthcare networks.

The proposal for Kenya is for a 1,000 women evaluation, while the Indonesian trial will initially cover 100 women.

TruScreen has also recently expanded sales in Saudi Arabia into public hospitals with the TruScreen Ultra2 cervical screening device demonstrating its value in timely diagnosis at a reduced cost compared with conventional screening methods.

Martin Dillon, CEO of TruScreen said “It is important that we continue with a growing pipeline of new market access activities to further grow the distribution of TruScreen cervical cancer screening technology. We expect Indonesia to be a key market for our technology in ASEAN, following our success in Vietnam. Similarly, Kenya is an important African market following our success in Zimbabwe”


This announcement has been approved by the Board.
ENDS
For more information, visit www.truscreen.com or contact:
Marty Dillion
Chief Executive Officer
[email protected]

Guy Robertson
Chief Financial Officer
[email protected]

---

Announcement PDF